Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model
Author: Labrinidis, A.
Hay, S.
Liapis, V.
Ponomarev, V.
Findlay, D.
Evdokiou, A.
Citation: Clinical Cancer Research, 2009; 15(10):3451-3461
Publisher: Amer Assoc Cancer Research
Issue Date: 2009
ISSN: 1078-0432
Statement of
Agatha Labrinidis, Shelley Hay, Vasilios Liapis, Vladimir Ponomarev, David M. Findlay and Andreas Evdokiou
Abstract: Purpose: To evaluate the efficacy of zoledronic acid (ZOL) against osteosarcoma (OS) growth, progression, and metastatic spread using an animal model of human OS that closely resembles the human disease. Experimental Design: Human K-HOS or KRIB OS cells, tagged or untagged with a luciferase reporter construct, were transplanted directly into the tibial cavity of nude mice. ZOL was given as weekly, or a single dose of 100 μg/kg body weight, equivalent to the 4 mg i.v. dose used clinically. Tumor growth at the primary site and as pulmonary metastases was monitored by bioluminescence imaging and histology, and OS-induced bone destruction was measured using high-resolution micro–computed tomography. Results: Mice transplanted with OS cells exhibited aberrant bone remodeling in the area of cancer cell transplantation, with areas of osteolysis mixed with extensive new bone formation extending from the cortex. ZOL administration prevented osteolysis and significantly reduced the amount of OS-induced bone formation. However, ZOL had no effect on tumor burden at the primary site. Importantly, ZOL failed to reduce lung metastasis and in some cases was associated with larger and more numerous metastatic lesions. Conclusions: Our data show that clinically relevant doses of ZOL, while protecting the bone from OS-induced bone destruction, do not inhibit primary tumor growth. Moreover, lung metastases were not reduced and may even have been promoted by this treatment, indicating that caution is required when the clinical application of the bisphosphonate class of antiresorptives is considered in OS.
Keywords: Tibia; Cell Line, Tumor; Osteoblasts; Animals; Mice, Inbred BALB C; Humans; Mice; Mice, Nude; Osteosarcoma; Osteolysis; Disease Progression; Diphosphonates; Imidazoles; Luciferases; Green Fluorescent Proteins; Recombinant Fusion Proteins; Tumor Burden; Luminescent Measurements; Xenograft Model Antitumor Assays; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Female; Bone Density Conservation Agents
RMID: 0020090759
DOI: 10.1158/1078-0432.CCR-08-1616
Appears in Collections:Orthopaedics and Trauma publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.